AXNX

Investor Moves

Investor	Portfolio Value	Portfolio Change	Position Change	Avg Buy Price	Current Price
George SorosSoros Fund Management $-73.1M ExitQ4 2024 $73M -- --
Ken GriffinCitadel Advisors $-16.3M ExitQ4 2024 $16M -- --
Jim SimonsRenaissance Technologies $-3.7M ExitQ4 2024 $3.7M -- --
Mario GabelliGAMCO Investors $-2.7M ExitQ4 2024 $2.7M -- --
Jeremy GranthamGMO $-2.1M ExitQ4 2024 $2.1M -- --
Ray DalioBridgewater Associates $-1.4M ExitQ4 2024 $1.4M -- --

Trade AXNX

About Axonics, Inc.

Axonics, Inc. is a medical device firm that focuses on developing and bringing to market sacral neuromodulation (SNM) solutions. These advanced SNM systems are designed to address a range of medical conditions, such as overactive bladder (including urinary urge incontinence and frequent urges to urinate), alongside fecal incontinence and non-obstructive urinary retention. The company's flagship rechargeable SNM System, known as r-SNM, operates by delivering gentle electrical impulses to specific sacral nerves, aiming to restore regular communication between the brain and the bladder or bowel, thereby lessening the symptoms of their dysfunction. Beyond its SNM portfolio, Axonics also provides Bulkamid, a urethral bulking agent for managing stress urinary incontinence in women. The firm distributes its offerings both through its dedicated sales team and a network of distributors across the United States, the United Kingdom, Germany, the Netherlands, the Nordic region, and other international markets. Established in 2012 and headquartered in Irvine, California, the company was initially known as Axonics Modulation Technologies, Inc., before officially changing its name to Axonics, Inc. in March 2021.

CEO: Raymond W. Cohen
IPO Date: Oct 31, 2018

Market Data

High: $70.98
Low: $70.98
Volume: 0
52W High: $70.98
52W Low: $70.98

Valuation

Market Cap: $3.6B
Enterprise Value: $3.6B

Financials

Free Cash Flow: $-5.6M
Revenue: $366M
Net Income: $-6.1M
Cash: $105M
Debt: $28M

Events

EarningsNov 7

EPS est. 0.13 · actual 0.16